GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Net Current Asset Value
中文

Connect Biopharma Holdings (Connect Biopharma Holdings) Net Current Asset Value

: $1.74 (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Connect Biopharma Holdings's net current asset value per share for the quarter that ended in Dec. 2023 was $1.74.

The historical rank and industry rank for Connect Biopharma Holdings's Net Current Asset Value or its related term are showing as below:

CNTB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.34   Med: 0.68   Max: 1.11
Current: 0.8

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Connect Biopharma Holdings was 1.11. The lowest was 0.34. And the median was 0.68.

CNTB's Price-to-Net-Current-Asset-Value is ranked better than
89.71% of 1030 companies
in the Biotechnology industry
Industry Median: 3.84 vs CNTB: 0.80

Connect Biopharma Holdings Net Current Asset Value Historical Data

The historical data trend for Connect Biopharma Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-0.79 -2.99 4.65 2.53 1.74

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only 4.65 3.20 2.53 2.22 1.74

Competitive Comparison

For the Biotechnology subindustry, Connect Biopharma Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Connect Biopharma Holdings Price-to-Net-Current-Asset-Value Distribution

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Price-to-Net-Current-Asset-Value falls into.



Connect Biopharma Holdings Net Current Asset Value Calculation

Connect Biopharma Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(120.971-24.849-0-0)/55.103
=1.74

Connect Biopharma Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(120.971-24.849-0-0)/55.103
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Connect Biopharma Holdings  (NAS:CNTB) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Connect Biopharma Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Connect Biopharma Holdings (Connect Biopharma Holdings) Headlines